Significant total near-term commitment of $115 million from Angelini Pharma, including a $65 million strategic equity investment and a $50 million upfront payment.
Organizations Involved
Angelini Pharma, Blackstone Life Sciences
Company Description
GRIN Therapeutics is a leader in the development of therapies to treat serious neurodevelopmental disorders, focusing on investigational drugs like radiprodil for rare genetic epilepsies.